MDXG MiMedx Group Inc.

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MIMEDX to Host First Quarter 2024 Operating and Financial Results Conference Call on April 30

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.

The conference call can be accessed using the following information:

Webcast:

U.S. Investors: 877-407-6184

International Investors: 201-389-0877

Conference ID: 13745475

A replay of the webcast will be available for approximately 30 days on the Company’s website at following the conclusion of the event.

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
16/04/2024

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Restructuring and Cost Reduction Initiative

MIMEDX Announces Restructuring and Cost Reduction Initiative Company Expects to Realize Annualized Savings of Approximately $40 Million MARIETTA, Ga., April 16, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced a series of cost reduction initiatives intended to prioritize growth opportunities, streamline operations and significantly reduce operating expenses. As part of these changes, the position of Chief Operating Officer, held by Ricci Whitlow, has been eliminated. “On behalf of the Board and management team, I want to thank Ricci...

April 16, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

MIMEDX to Sponsor Leading Advanced Wound Care Conferences Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care (“SAWC”) Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (“DLS”) Conference. Through scientific presentations, clinician edu...

April 2, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Launch of CHORIOFIX™

MIMEDX Announces Launch of CHORIOFIX™ Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. “CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer,” stated Michelle Massee, MIMEDX VP, Research & Development. “It...

March 23, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX®...

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields Bolsters Surgical offering with product specifically designed for use in endocrine procedures MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company’s AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts. AMNIOFIX Thyroid Shields are allografts designed and intended for use in endocrine surgery. Following a thyroidectomy,...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating an...

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Mi...

February 25, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch